PCI in Left Main Disease: Do the Guidelines in the US Reflect the Current State of Knowledge?

Issam D. Moussa, MD

Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida



Disclosure Statement of Financial Interest

 I, (Issam Moussa) DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation

US Guidelines 2011



2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

Writing Committee Members*

Glenn N. Levine, MD, FACC, FAHA, Chair⁺ Eric R. Bates, MD, FACC, FAHA, Vice Chair^{*}⁺ James C. Blankenship, MD, FACC, FSCAI, Vice Chair^{*}[±]

Steven R. Bailey, MD, FACC, FSCAI*‡ John A. Bittl, MD, FACC†§ Bojan Cercek, MD, FACC, FAHA† Charles E. Chambers, MD, FACC, FSCAI‡ Stephen G. Ellis, MD, FACC*† Robert A. Guyton, MD, FACC*† Steven M. Hollenberg, MD, FACC*† Umesh N. Khot, MD, FACC*† Richard A. Lange, MD, FACC, FAHA§ Laura Mauri, MD, MSc, FACC, FSCAI* Roxana Mehran, MD, FACC, FAHA, FSCAI* Issam D. Moussa, MD, FACC, FAHA, FSCAI Debabrata Mukherjee, MD, FACC, FSCAI Brahmajee K. Nallamothu, MD, FACC Henry H. Ting, MD, FACC, FAHA

*Writing committee members are required to recuse themselves from voting on sections to which their specific relationship with industry and other entities may apply; see Appendix 1 for recusal information. ‡ACCF/AHA Representative. ‡SCAI Representative. §Joint Revascularization Section Author. #ACCF/AHA Task Force on Practice Guidelines Liaison. ¶ACCF/AHA Task Force on Performance Measures Liaison.

Heart Team Approach to UPLM or Complex CAD

Anatomic Setting	COR	LOE
UPLM or Complex	I – Heart Team Approach	С
CAD		
UPLM or Complex	IIa – Calculation of the	В
CAD	STS and SYNTAX	
	scores	



UPLM PCI to Improve Survival (SIHD)


Risk of PCI Complication	Likelihood of Good Long-term Outcome	CABG Mortality Risk	COR	LOE
Low	Hi	Hi	IIa—For SIHD when <i>low</i> risk of PCI complications and <i>high</i> likelihood of good long-term outcome (e.g., SYNTAX score of ≤22, ostial or trunk left main CAD), <u>and</u> a <i>signficantly</i> <i>increased</i> CABG risk (e.g., STS-predicted risk of operative mortality ≥5%)	В
L			IIb—For SIHD when <i>low to intermediate</i> risk of PCI complications and <i>intermediate to high</i> likelihood of good long-term outcome (e.g., SYNTAX score of <33, bifurcation left main CAD) <u>and</u> <i>increased</i> CABG risk (e.g., moderate- severe COPD, disability from prior stroke, prior cardiac surgery, STS-predicted operative mortality >2%)	В
Hi	Low	Low	III: Harm—For SIHD in patients (versus performing CABG) with unfavorable anatomy for PCI and who are good	В
			candidates for CABG	

UPLM PCI to Improve Survival (ACS)


COR	LOE
IIa—For UA/NSTEMI if not a CABG candidate	В
IIa—For STEMI when distal coronary flow is <timi 3="" and="" be="" can="" grade="" pci="" performed<br="">more rapidly and safely than CABG</timi>	С

The Evidence





MACCE to 3 Years in Patients with UPLMCA Disease (All Syntax Patients)



MACCE to 3 Years in Patients with UPLMCA Disease According to SYNTAX Score





Table 1 Studies Included in the Meta-Analysis

Study/First Author (Ref. #)	Year	Design	N	PCI, n	DES, %	CABG, n	LIMA to LAD, %	Primary Outcome
LEMANS (4)	2008	RCT	105	52	35	53	81	Cardiac death, MI, CVA, repeat revascularization, and/or acute/subacute in-stent thrombosis
SYNTAX Left Main (5)	2009	Pre-specified subanalysis from RCT	705	357	100	348	97	All-cause death, CVA, MI, and repeat revascularization
Boudriot et al. (8)	2010	RCT	201	100	100	101	99	All-cause death, MI, and repeat revascularization
PRECOMBAT (9)	2011	RCT	600	300	100	300	94	All-cause death, CVA, MI, and repeat revascularization

Major Adverse Cardiac and Cerebrovascular Events

Model	Study name	Sta	tistics fo	or each	study	Events / Total			
		Oddis ratio	Lower limit	Upper limit	p-Value	PCI	CABG		
	LEMANS	1.368	0.579	3.229	0.475	16/52	13 / 53		
	SYNTAX left main	1.181	0.774	1.801	0.440	56/355	46/336		
	Boudriot et al.	1.458	0.686	3.098	0.327	19 / 100	14 / 101		
	PRECOMBAT	1.328	0.725	2.436	0.359	26 / 300	20/300		
Fixed	Pooled estimate	1.276	0.950	1.715	0.106				
Random	Pooled estimate	1.276	0.950	1.715	0.106				
	l ² = 0%								




Odds ratio and 95% CI

Favors PCI Favors CABG

0.01

Death, Myocardial Infarction or Stroke

Model	Study name	Sta	tistics fo	or each	study	Events / Total			Odds r	Odds ratio and 95% Cl		
		Oddis ratio	Lower limit	Upper limit	p-Value	PCI	CABG					
	SYNTAX left main	0.745	0.430	1.291	0.294	25/355	31 / 336			-		
	PRECOMBAT	0.828	0.352	1.946	0.664	10/300	12/300					
Fixed	Pooled estimate	0.769	0.484	1.220	0.264					•		
Random	Pooled estimate	0.769	0.484	1.220	0.264					•		
	l ² = 0%							0.01	0.1	1	10	100
								Fa	vors PC	l Fav	ors CAE	3G



Cappodanno D et al. J Am Coll Cardiol 2011;58:1426-32

Random Pooled estimate

 $|^2 = 0\%$

2.246

1.537 3.282

0.000

Death Model Study name Odds ratio and 95% CI Statistics for each study Events / Total Odds Lower Upper limit limit p-Value PCI CABG ratio LEMANS 0.240 0.026 2.225 0.209 1/52 4/53SYNTAX left main 0.944 1.963 0.878 15/355 15/336 0.454 Boudriot et al. 2.069 0.270 2/100 5/101 0.392 0.074 PRECOMBAT 0.745 0.255 2.173 0.590 6/300 8/300 0.741 1.284 0.285 Fixed Pooled estimate 0.427 Random Pooled estimate 0.741 0.427 1.284 0.285 $|^2 = 0\%$ 0.01 0.1 10 100 1 Favors PCI Favors CABG Myocardial Infarction Model Study name Statistics for each study Odds ratio and 95% CI Events / Total Odds Lower Upper ratio limit limit p-Value PCI CABG LEMANS 3.248 0.340 1/52 3/53 0.327 0.033 0.969 15 / 355 14 / 336 SYNTAX left main 1.015 0.482 2.136 Boudriot et al. 1.010 0.199 5.129 0.990 3/100 3/101 PRECOMBAT 0.705 4/300 3/300 1.338 0.297 6.029 0.981 Fixed Pooled estimate 0.541 1.781 0.950 Random Pooled estimate 0.981 0.541 1.781 0.950 $l^2 = 0\%$ 0.01 0.1 10 100 1 Favors PCI Favors CABG

Stroke Odds ratio and 95% Cl Statistics for each study Events / Total Model Study name Odds Lower Upper ratio limit limit p-Value PCI CABG LEWANS 0.297 0/52 2/53 0.009 4,187 0.196 SYNTAX left main 0.116 0.014 0.931 0.043 1/355 8/336 PRECOMBAT 0.199 0.009 4,156 0.298 0/300 2/300 0.671 0.013 Fixed Pooled estimate 0.150 0.033 Random Pooled estimate 0.150 0.033 0.671 0.013 $|^2 = 0\%$ 0.01 0.1 1 10 100 Favors PCI Favors CABG Repeat Revascularization Model Study name Statistics for each study Events / Total Odds ratio and 95% CI Odds Lower Upper limit ratio limit p-Value PCI CABG LEMANS 3.892 1.297 11.683 0.015 15/52 5/53 SYNTAX left main 2.072 1.215 3.532 0.007 45/355 22/336 Boudriot et al. 2.578 0.948 7.006 0.063 14 / 100 6 / 101 PRECOMBAT 1.851 4.079 0.127 18/300 10/300 0.840 Fixed Pooled estimate 2.246 1.537 3.282 0.000

Favors PCI Favors CABG

10

100



Cappodanno D et al. J Am Coll Cardiol 2011;58:1426-32

0.01

0.1

Major Adverse Cardiac and Cerebrovascular Events

Model	Group by	Study name	Subgroup within study	Sta	Statistics for each study Eve			Events	/ Total	Odds ratio and 95% Cl
	Subgroup within study			Odds ratio	Lower limit	Upper limit	p-Value	PCI	CABG	
	Isolated LMCA	SYNTAX LM	Isolated LMCA	0.83	0.17	3.93	0.81	3/42	4 / 47	
	Isolated LMCA	PRECOMBAT	Isolated LMCA	0.40	0.04	4.05	0.44	1/27	3/34	-+
Fixed	Isolated LMCA			0.66	0.18	2.40	0.53	4/69	7/81	
Random	Isolated LMCA			0.66	0.18	2.40	0.53	4/69	7/81	-
	LMCA + 1 vessel	SYNTAX LM	LMCA + 1 vessel	0.53	0.17	1.67	0.28	5/67	9/68	
	LMCA + 1 vessel	PRECOMBAT	LMCA + 1 vessel	0.69	0.11	4.34	0.70	2/50	3/53	
Fixed	LMCA + 1 vessel			0.57	0.22	1.51	0.26	7/117	12/121	
Random	LMCA + 1 vessel			0.57	0.22	1.51	0.26	7/117	12/121	
	LMCA + 2 vessels	SYNTAX LM	LMCA + 2 vessels	1.47	0.71	3.01	0.30	22/111	15/104	🖶
	LMCA + 2 vessels	PRECOMBAT	LMCA + 2 vessels	1.06	0.45	2.50	0.89	13/101	11/90	+
Fixed	LMCA + 2 vessels			1.28	0.74	2.23	0.38	35/212	26 / 194	🔶
Random	LMCA + 2 vessels			1.28	0.74	2.23	0.38	35/212	26 / 194	🔶
	LMCA + 3 vessels	SYNTAX LM	LMCA + 3 vessels	1.31	0.68	2.54	0.42	26/135	18/117	🗕
	LMCA + 3 vessels	PRECOMBAT	LMCA + 3 vessels	3.25	1.32	8.00	0.01	20/122	7/123	-=-
Fixed	LMCA + 3 vessels			1.80	1.06	3.07	0.03	48/257	25/240	
Random	LMCA + 3 vessels			1.96	0.81	4.73	0.14	46 / 257	25 / 240	🔶

0.01 0.1 1 10 100

PCI vs. CABG for UPLMCA Disease with SYNTAX Score <32 A Propensity Score Matched 3-Year Comparison

	Log Hazard Ratio	HR	LCL	UCL	р
Death/MI/CVA					
Unadjusted		1.30	0.72	2.15	0.892
Adjusted with SYNTAX score and Euroscore		0.83	0.44	1.57	0.573
Adjusted with covariates		0.73	0.37	1.44	0.365
Adjusted with propensity score		0.79	0.41	1.53	0.485
Adjusted with covariates and propensity score	_ •	0.73	0.37	1.43	0.360
MACCE					
Unadjusted	_ 	2.60	1.63	4.14	< 0.001
Adjusted with SYNTAX score and Euroscore	_ 	2.17	1.34	3.51	0.002
Adjusted with covariates		2.39	1.45	3.95	0.001
Adjusted with propensity score	─	2.38	1.45	3.93	0.001
Adjusted with covariates and propensity score		2.39	1.45	3.94	0.001
0,1	1	10			

Log Odds Ratio

Do the Guidelines in the US Reflect the Current State of Knowledge?



Remaining Questions



- What is the cause of the higher mortality after PCI in patients with LMCA and SYNTAX >32?
 - CABG benefit? (CABG did not reduce mortality in STITCH and BARI 2D compared to medical therapy)
 - TAXUS stents harm? (too many stents, high thrombosis and restenosis rate)
- What the impact of increasing co-morbidities on SYNTAX outcome? Can we apply the results to patients with STS score >5?
- Can new PCI strategies and 2nd generation devices change the outcome?
 - Use of FFR guided PCI in MVD improve outcome
 - 2nd generation stents have lower rates of thrombosis and restenosis